- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06571045
A Study to Evaluate the Efficacy and Safety of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME (BRUNELLO)
Um estudo randomizado, duplo-mascarado, multicêntrico e de 3 braços de fase 2/3 para avaliar a eficácia e segurança do EYE103 intravítreo em comparação com ranibizumabe intravítreo (0,5 mg) em participantes com edema macular diabético
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig (EYE103) in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME)
In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval algorithm.
Approximately 960 participants will be entered in the study.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
EYE-RES-102 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of remigromig in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME)
Approximately 960 participants will be entered in the study. Participants will be randomized 1:1:1 to receive low dose remigromig, high dose remigromig, or 0.5 mg ranibizumab, administered via intravitreal injection. In the first year, all 3 treatment groups will be treated every 4 weeks with either remigromig or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shift based on a personalized treatment interval (PTI) algorithm. Throughout the 2-year study, subjects will be evaluated every 4 weeks, including measurement of Early Treatment of Diabetic Retinopathy Study (ETDRS) Best-Corrected Visual Acuity (BCVA), examination by slit-lamp biomicroscopy, fundoscopy, and spectral domain optical coherence tomography (SD-OCT). Among other parameters, SD-OCT will be used to measure central subfield thickness (CST) in microns.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
- Fase 3
Contactos e Locais
Locais de estudo
-
-
-
Frankfurt, Alemanha, 60590
- Frankfurt, Germany
-
Hanover, Alemanha, 30625
- Hanover, Germany
-
München, Alemanha, 80336
- Munchen, Germany
-
Münster, Alemanha, 48145
- Munster, Germany
-
-
-
-
-
CABA, Argentina, 1023
- Buenos Aires, Argentina
-
Córdoba, Argentina, X5000AAJ
- Ciudad de Cordoba, Argentina
-
-
Buenos Aires
-
CABA, Buenos Aires, Argentina, 1015
- Buenos Aires, Argentina
-
CABA, Buenos Aires, Argentina, 1120
- Buenos Aires, Argentina
-
CABA, Buenos Aires, Argentina, C1033AAW
- Buenos Aires, Argentina
-
Caba, Buenos Aires, Argentina, C1116ABA
- Caba, Buenos Aires, Argentina
-
-
Córdoba Province
-
Córdoba, Córdoba Province, Argentina, 5000
- Cordoba, Argentina
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, S2000DSK
- Santa Fe, Argentina
-
-
Sante Fe
-
Rosario, Sante Fe, Argentina, 2000
- Santa Fe, Argentina
-
-
-
-
-
Albury, Austrália, 2640
- Albury, Australia
-
Parramatta, Austrália, 2150
- Parramatta, Australia
-
Sydney, Austrália, 2000
- Sydney, Australia
-
-
New South Wales
-
Sydney, New South Wales, Austrália, 2000
- Sydney Retina Clinic
-
Sydney, New South Wales, Austrália, 2135
- Sydney, Australia
-
-
-
-
-
Medellín, Colômbia, 50016
- Medellin, Colombia
-
-
Antioquia
-
Medellín, Antioquia, Colômbia, 50021
- Medellin, Colombia
-
-
Atlántico
-
Barranquilla, Atlántico, Colômbia, 80002
- Barranquilla, Colombia
-
-
Columbia
-
Bogotá, Columbia, Colômbia, 110231
- Bogota, Columbia
-
-
Valle del Cauca Department
-
Cali, Valle del Cauca Department, Colômbia, 760042
- Cali, Colombia
-
-
-
-
-
Osijek, Croácia, 31000
- Osijek, Croatia
-
-
-
-
-
Trebišov, Eslováquia, 075 01
- Trebisov, Slovakia
-
Trenčín, Eslováquia, 911 01
- Trencin, Slovakia
-
Žilina, Eslováquia, 012 07
- Zilina, Slovakia
-
-
-
-
-
Barcelona, Espanha, 08035
- Barcelona, Spain
-
Barcelona, Espanha, 08021
- Barcelona, Spain
-
Barcelona, Espanha, 08022
- Barcelona, Spain
-
Barcelona, Espanha, 08195
- Barcelona, Spain
-
Santiago de Compostela, Espanha, 15706
- Santiago de Compostela, Spain
-
Seville, Espanha, 41009
- Sevilla, Spain
-
Zaragoza, Espanha, 50009
- Zaragoza, Spain
-
-
Valencia
-
Burjassot, Valencia, Espanha, 46100
- Valencia, Spain
-
-
-
-
Arizona
-
Scottsdale, Arizona, Estados Unidos, 85255
- Scottsdale
-
-
Arkansas
-
Fayetteville, Arkansas, Estados Unidos, 72703
- Fayetteville, Arkansas
-
Springdale, Arkansas, Estados Unidos, 72764
- Springdale, Arkansas
-
-
California
-
Bakersfield, California, Estados Unidos, 93309
- Bakersfield, CA
-
Glendale, California, Estados Unidos, 91204
- Glendale, CA
-
Modesto, California, Estados Unidos, 95356
- Modesto, CA
-
Mountain View, California, Estados Unidos, 94040
- Mountain View, CA
-
Redlands, California, Estados Unidos, 92374
- Redlands, CA
-
Sacramento, California, Estados Unidos, 95825
- Sacramento, CA
-
Sacramento, California, Estados Unidos, 95841
- Sacramento, CA
-
Santa Ana, California, Estados Unidos, 92705
- Santa Ana
-
-
Colorado
-
Colorado Springs, Colorado, Estados Unidos, 80909
- Colorado Springs, CO
-
Denver, Colorado, Estados Unidos, 80210
- Denver, Colorado
-
-
Connecticut
-
Danbury, Connecticut, Estados Unidos, 06810
- Danbury, CT
-
Manchester, Connecticut, Estados Unidos, 06042
- Manchester, CT
-
Waterford, Connecticut, Estados Unidos, 06385
- Waterford,CT
-
-
Florida
-
Deerfield Beach, Florida, Estados Unidos, 33064
- Deerfield Beach, FL
-
Fort Lauderdale, Florida, Estados Unidos, 33308
- Fort Lauderdale, FL
-
Fort Myers, Florida, Estados Unidos, 33912
- Fort Myers,FL
-
Gainesville, Florida, Estados Unidos, 32607
- Gainesville, FL
-
Orlando, Florida, Estados Unidos, 32806
- Orlando, Florida
-
Plantation, Florida, Estados Unidos, 33324
- Plantation, FL
-
Sarasota, Florida, Estados Unidos, 34232
- Sarasota, FL
-
St. Petersburg, Florida, Estados Unidos, 33711
- Saint Petersburg, FL
-
Tallahassee, Florida, Estados Unidos, 32308
- Tallahassee, FL
-
Tampa, Florida, Estados Unidos, 33609-4614
- Tampa, FL
-
Tampa, Florida, Estados Unidos, 33617
- Tampa, FL
-
Winter Haven, Florida, Estados Unidos, 33880
- Winter Haven, FL
-
-
Illinois
-
Lemont, Illinois, Estados Unidos, 60439
- Lemont, IL
-
Springfield, Illinois, Estados Unidos, 62702
- Springfield, Illinois
-
-
Iowa
-
West Des Moines, Iowa, Estados Unidos, 50266
- West Des Moines, IA
-
-
Kansas
-
Lenexa, Kansas, Estados Unidos, 66215
- Lenexa, Kansas
-
Wichita, Kansas, Estados Unidos, 67214
- Wichita, Kansas
-
-
Maine
-
Portland, Maine, Estados Unidos, 04101
- Portland, Maine
-
-
Maryland
-
Hagerstown, Maryland, Estados Unidos, 21740
- Hagerstown, MD
-
-
Massachusetts
-
Springfield, Massachusetts, Estados Unidos, 01107
- Springfield,MA
-
-
Michigan
-
Grand Rapids, Michigan, Estados Unidos, 49546
- Grand Rapids, Michigan
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55435
- Minneapolis, MN
-
-
Mississippi
-
Madison, Mississippi, Estados Unidos, 39110
- Madison, MS
-
-
New Jersey
-
Bloomfield, New Jersey, Estados Unidos, 07003
- Bloomfield, NJ
-
Cherry Hill, New Jersey, Estados Unidos, 08034
- Cherry Hill, NJ
-
-
New York
-
Liverpool, New York, Estados Unidos, 13088
- Liverpool, NY
-
Oceanside, New York, Estados Unidos, 11572
- Oceanside, NY
-
Rochester, New York, Estados Unidos, 14620
- Rochester, NY
-
-
North Carolina
-
Asheville, North Carolina, Estados Unidos, 28803
- Asheville, NC
-
Hickory, North Carolina, Estados Unidos, 28602
- Hickory, NC
-
Wake Forest, North Carolina, Estados Unidos, 27587
- Wake Forest, MC
-
Winston-Salem, North Carolina, Estados Unidos, 27103
- Winston Salem, NC
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44122
- Cleveland, Ohio
-
Cleveland, Ohio, Estados Unidos, 44130
- Cleveland, OH
-
Youngstown, Ohio, Estados Unidos, 44505
- Youngstown, Ohio
-
-
Oklahoma
-
Edmond, Oklahoma, Estados Unidos, 73013
- Edmond, OK
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97221
- Portland, OR
-
Springfield, Oregon, Estados Unidos, 97477
- Springfield, Oregon
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Estados Unidos, 18017
- Bethlehem, PA
-
Erie, Pennsylvania, Estados Unidos, 16507
- Erie, PA
-
-
South Carolina
-
Beaufort, South Carolina, Estados Unidos, 29902
- Beaufort, SC
-
Florence, South Carolina, Estados Unidos, 29501
- Florence, SC
-
Ladson, South Carolina, Estados Unidos, 29456
- Ladson, SC
-
West Columbia, South Carolina, Estados Unidos, 29169
- West Columbia, SC
-
-
Tennessee
-
Germantown, Tennessee, Estados Unidos, 38138
- Germantown, TN
-
Hixson, Tennessee, Estados Unidos, 37343
- Hixson, Tennessee
-
Johnson City, Tennessee, Estados Unidos, 37604
- Johnson City, Tennessee
-
Knoxville, Tennessee, Estados Unidos, 37922
- Knoxville, TN
-
Nashville, Tennessee, Estados Unidos, 37203
- Nashville, TN
-
-
Texas
-
Abilene, Texas, Estados Unidos, 79606
- Abilene, TX
-
Amarillo, Texas, Estados Unidos, 79109
- Amarillo, TX
-
Amarillo, Texas, Estados Unidos, 79106
- Amarillo, TX
-
Arlington, Texas, Estados Unidos, 76012
- Arlington, TX
-
Austin, Texas, Estados Unidos, 78705
- Austin, TX
-
Beaumont, Texas, Estados Unidos, 77707
- Beaumont, TX
-
Bellaire, Texas, Estados Unidos, 77401
- Bellaire, TX
-
Dallas, Texas, Estados Unidos, 75231
- Dallas, TX
-
Fort Worth, Texas, Estados Unidos, 76104
- Fort Worth, TX
-
Katy, Texas, Estados Unidos, 77494
- Katy, TX
-
Plano, Texas, Estados Unidos, 75075
- Plano, TX
-
Round Rock, Texas, Estados Unidos, 78681
- Round Rock, TX
-
San Antonio, Texas, Estados Unidos, 78240
- San Antonio, TX
-
Schertz, Texas, Estados Unidos, 78154
- Schertz, Texas
-
The Woodlands, Texas, Estados Unidos, 77384
- The Woodlands, TX
-
Willow Park, Texas, Estados Unidos, 76087
- Willow Park, TX
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84107
- Salt Lake City, Utah
-
-
Virginia
-
Lynchburg, Virginia, Estados Unidos, 24502
- Lynchburg, VA
-
Richmond, Virginia, Estados Unidos, 23235
- Richmond, Virginia
-
-
Washington
-
Spokane, Washington, Estados Unidos, 99204
- Spokane, WA
-
-
-
-
-
Créteil, França, 94010
- Creteil, France
-
Lyon, França, 69004
- Lyon, France
-
Marseille, França, 13008
- Marseille, France
-
Paris, França, 75006
- Paris, France
-
Paris, França, 75015
- Paris, France
-
Paris, França, 75019
- Paris, France
-
Saint-Cyr-sur-Loire, França, 37540
- Saint Cyr sur Loire, France
-
-
Cedex
-
Dijon, Cedex, França, 21079
- Cedex, France
-
-
-
-
-
Budapest, Hungria, H-1062
- Budapest, Hungary
-
Budapest, Hungria, H-1085
- Budapest, Hungary
-
Budapest, Hungria, H-1106
- Budapest, Hungary
-
Budapest, Hungria, H-1133
- Budapest, Hungry
-
Debrecen, Hungria, H-4032
- Debrecen, Hungary
-
Pécs, Hungria, H-7621
- Pecs, Hungary
-
Szeged, Hungria, H-6720
- Szeged, Hungary
-
Zalaegerszeg, Hungria, 8900
- Zalaegerszeg, Hungary
-
-
-
-
-
Be’er Ya‘aqov, Israel, 70300
- Beer Yakov, Israel
-
Haifa, Israel, 3436212
- Haifa, Israel
-
Jerusalem, Israel, 9112001
- Jerusalem, Israel
-
Petah Tikva, Israel, 49100
- Petah Tikva, Israel
-
Rehovot, Israel, 76100
- Rehovot, Israel
-
Tel Aviv, Israel, 6423906
- Tel Aviv, Israel
-
-
-
-
-
Bologna, Itália, 40138
- Bologna, Italy
-
Florence, Itália, 50139
- Firenze, Italy
-
Milan, Itália, 20122
- Milano, Italy
-
Milan, Itália, 20132
- Milano, Italy
-
Milan, Itália, 20157
- Milano, Italy
-
Roma, Itália, 00168
- Roma, Italy
-
Rome, Itália, 81.00133
- Rome, Italy
-
Udine, Itália, 33100
- Udine, Italy
-
-
-
-
-
Riga, Letônia, LV1002
- Riga, Latvia
-
Riga, Letônia, LV1006
- Riga, Latvia
-
-
-
-
-
Bialystok, Polônia, 15-866
- Bialystok, Poland
-
Bydgoszcz, Polônia, 85-309
- Bydgoszcz, Poland
-
Bydgoszcz, Polônia, 85-631
- Bydgoszcz, Poland
-
Gdansk, Polônia, 80-809
- Gdansk, Poland
-
Katowice, Polônia, 40-594
- Katowice, Poland
-
Krakow, Polônia, 31-501
- Krakow, Poland
-
Olsztyn, Polônia, 10-424
- Olsztyn, Poland
-
Tarnowskie Góry, Polônia, 42-600
- Tarnowskie Gory, Poland
-
-
Gdansk
-
Gdansk, Gdansk, Polônia, 80-809
- Gdansk, Poland
-
-
-
-
PR
-
Arecibo, PR, Porto Rico, 00612
- Arecibo, PR
-
-
-
-
-
Coimbra, Portugal, 3000-548
- Coimbra, Portugal
-
Coimbra, Portugal, 3030-163
- Coimbra, Portugal
-
Porto, Portugal, 4200-319
- Porto, Portugal
-
-
-
-
-
Bradford, Reino Unido, BD9 6RJ
- Bradford, United Kingdom
-
Bristol, Reino Unido, BS1 2LX
- Bristol, UK
-
Liverpool, Reino Unido, L7 8YA
- Liverpool, United Kingdom
-
Sunderland, Reino Unido, SR2 9HP
- Sunderland, United Kingdom
-
Wolverhampton, Reino Unido, WV10 0QP
- Wolverhamptom, United Kingdom
-
-
Middlesex
-
London, Middlesex, Reino Unido, NW10 7NS
- London, UK
-
-
UnitedKingdom
-
York, UnitedKingdom, Reino Unido, YO10 4DZ
- York, United Kingdom
-
-
-
-
-
Mladá Boleslav, Tcheca, 293 01
- Mlada Boleslav, Czechia
-
Náchod, Tcheca, 547 01
- Nachod, Czechia
-
Prague, Tcheca, 1150/50
- Prague, Czechia
-
Prague, Tcheca
- Prague, Czechia
-
-
-
-
Turkey
-
Ankara, Turkey, Turquia (Türkiye), 06230
- Ankara, Turkey
-
Ankara, Turkey, Turquia (Türkiye), 06490
- Ankara, Turkey
-
Balçova, Turkey, Turquia (Türkiye), 35330
- Balcova, Turkey
-
-
-
-
-
Graz, Áustria, 8036
- Graz, Austria
-
Innsbruck, Áustria, 6020
- Innsbruck, Austria
-
Vienna, Áustria, 1090
- Vienna, Austria
-
Vienna, Áustria, 1140
- Vienna, Austria
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity
- Be male or female ≥18 years of age.
- Have type 1 or type 2 diabetes mellitus and a hemoglobin A1c (HbA1c) of ≤12%.
- Have a decrease in vision in the study eye determined by the investigator to be primarily the result of diabetic macular edema (DME).
Exclusion Criteria:
-
Be pregnant or breastfeeding
-
History of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of Screening
-
Have any treatment for complications of cataract surgery with steroids or yttrium aluminum garnet (YAG) laser capsulotomy within 90 days of Screening
-
Are currently using drugs with known retinal toxicity (e.g., Hydroxychloroquine, pentosan polysulfate sodium, and amiodarone)
-
If treatment-experienced for DME have a history of any of the following treatments within the noted time windows:
- Have had prior treatment in the study eye with 8 mg aflibercept (EYLEA HD) or faricimab (VABYSMO) within 120 days prior to the Screening visit in the study eye
- Have had an IVT with other anti-VEGF treatments (ranibizumab, bevacizumab, aflibercept [2 mg], brolucizumab, pegaptanib sodium) in the study eye within 90 days of the Screening visit
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Remigromig Low Dose Treatment Arm
Remigromig Low Dose Treatment Arm |
Remigromig is a humanized antibody formulated for intravitreal administration
Outros nomes:
|
|
Experimental: Remigromig High Dose Treatment Arm
Remigromig High Dose Treatment Arm |
Remigromig is a humanized antibody formulated for intravitreal administration
Outros nomes:
|
|
Comparador Ativo: Ranibizumab Treatment Arm
Ranibizumab Treatment Arm |
Ranibizumab is a commercially available anti-VEGF treatment formulated for intravitreal administration for use in patients with diabetic macular edema
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from baseline in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart
Prazo: Baseline and Week 52
|
The change from baseline in Best-Corrected Visual Acuity (BCVA) measured using the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart will be presented. |
Baseline and Week 52
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change from Baseline in Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) at Week 52
Prazo: Baseline and Week 52
|
The change from baseline in Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) at Week 52 will be presented. |
Baseline and Week 52
|
|
Superiority Hypothesis: Change from Baseline in ETDRS BCVA at Week 52
Prazo: Baseline and Week 52
|
The Superiority Hypothesis: change from baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS) Best-Corrected Visual Acuity (BCVA) at Week 52 will be presented. |
Baseline and Week 52
|
|
Time to Absence of Diabetic Macular Edema (DME)
Prazo: Up to approximately Week 104
|
The time to absence of Diabetic Macular Edema (DME) defined as Optical Coherence Tomography (OCT) Central Subfield Thickness (CST) of <300 μm will be presented. |
Up to approximately Week 104
|
|
Time to Gaining ≥15 ETDRS letters
Prazo: Up to approximately Week 52
|
The time to gaining ≥15 letters on the standardized Early Treatment of Diabetic Retinopathy Study (ETDRS) chart will be presented. |
Up to approximately Week 52
|
|
Proportion of Participants with Resolution of Macular Leakage on FA at Week 24
Prazo: Up to approximately Week 24
|
The proportion of participants with resolution of macular leakage on fluorescein angiography (FA), defined as 0 to 1 mm^2, at Week 24 will be presented. |
Up to approximately Week 24
|
|
Proportion of Participants Without Intraretinal and Subretinal Fluid at the Foveal Center on OCT at Week 52
Prazo: Up to approximately Week 52
|
The proportion of participants without intraretinal and subretinal fluid at the foveal center on Optical Coherence Tomography (OCT) at Week 52 will be presented. |
Up to approximately Week 52
|
|
Change from Baseline in Focal Area Zone (FAZ) area on fluorescein angiography (FA) at Week 52
Prazo: Baseline and Week 52
|
The change from baseline in Focal Area Zone (FAZ) area on fluorescein angiography (FA) at Week 52 will be presented. |
Baseline and Week 52
|
|
Proportion of Participants Achieving 20/40 or Better BCVA at Week 52
Prazo: Up to approximately Week 52
|
The proportion of participants who achieve 20/40 or better Best-Corrected Visual Acuity (BCVA) at Week 52 will be presented. |
Up to approximately Week 52
|
|
Number of Participants Who Experience an Ocular and/or Systemic Adverse Event (AE)
Prazo: Up to approximately 104 Weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an ocular and/or systemic AE will be reported. |
Up to approximately 104 Weeks
|
|
Number of Participants Who Experience an Ocular and/or Systemic Serious Adverse Event (SAE)
Prazo: Up to approximately 104 Weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an ocular and/or systemic serious adverse event (SAE) will be reported. |
Up to approximately 104 Weeks
|
|
Number of Participants Who Discontinue Study Treatment Due to an AE
Prazo: Up to approximately 104 Weeks
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported. |
Up to approximately 104 Weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Charles Miller, MD PhD, EyeBiotech Ltd.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- EYE-RES-102
- MK-3000-001 (Outro identificador: MSD)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .